OVID has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OVID has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Ovid Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.27 Mil. Ovid Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $14.43 Mil. Ovid Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-68.06 Mil. Ovid Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.23.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Ovid Therapeutics's Debt-to-EBITDA or its related term are showing as below:
During the past 9 years, the highest Debt-to-EBITDA Ratio of Ovid Therapeutics was -0.26. The lowest was -0.31. And the median was -0.29.
The historical data trend for Ovid Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | - | - | - | -0.31 | -0.28 |
Ovid Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.29 | -0.30 | -0.35 | -0.23 | -0.23 |
For the Biotechnology subindustry, Ovid Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Ovid Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.246 | + | 14.756) | / | -57.686 | |
= | -0.28 |
Ovid Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.268 | + | 14.43) | / | -68.06 | |
= | -0.23 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.
Ovid Therapeutics (NAS:OVID) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Ovid Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Jason Tardio | officer: Chief Commercial Officer | 1460 BROADWAY, NEW YORK NY 10036 |
Takeda Pharmaceuticals U.s.a., Inc. | 10 percent owner | ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
Kevin Joseph Fitzgerald | director | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Amit Rakhit | officer: CMO and PMO | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Robert Michael Poole | director | 200 W. HIGHLAND DR., #303, SEATTLE WA 98119 |
Jeffrey A Rona | officer: Chief Business Officer | 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Jeremy M Levin | director, 10 percent owner, officer: CEO | |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Thomas Michael Perone | officer: SVP, General Counsel | 1460 BROADWAY, NEW YORK NY 10036 |
Karen Bernstein | director | C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034 |
Millennium Pharmaceuticals Inc | 10 percent owner | 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Douglas E Williams | director | C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799 |
Ana Ward | officer: SVP and General Counsel | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Timothy Daly | officer: VP, Finance & Corp. Controller | 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 05-20-2022
By Value_Insider Value_Insider • 11-08-2022
By GuruFocusNews GuruFocusNews • 06-09-2022
By Value_Insider Value_Insider • 12-02-2022
By Marketwired • 06-26-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By Marketwired • 11-03-2023
By Marketwired • 10-10-2023
By GuruFocusNews GuruFocusNews • 05-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.